Post
Akero’s NASH candidate and Ozempic reduce liver fat in Phase IIb cohort
New Phase IIb data suggests a combination therapy of Akero Therapeutics’s efruxifermin and Novo Nordisk’s Ozempic (semaglutide) can reduce liver …
ASCO 2023: Janssen present positive follow-up data for first in line therapy for lung cancer
Janssen Pharmaceuticals has presented long-term results from its CHRYSALIS study, which showed the combination of Rybrevant (amivantamab-vmjw) and lazertinib, was …
ASCO 2020: Janssen reports positive results for Talquetamab in Multiple myeloma
Johnson & Johnson (J&J) has reported results from its Phase I studies investigating talquetamab as a monotherapy and in combination …
ASCO 2023: Research backs chemo-only approach for some rectal cancer patients
Results unveiled at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting indicate that some patients with locally advanced …
Servier’s Phase III INDIGO trial of vorasidenib meets endpoints
Servier has reported that the Phase III INDIGO trial of vorasidenib in patients with recurrent or residual grade 2 isocitrate …
AstraZeneca reports positive results from ADAURA Phase III trial
AstraZeneca has reported positive results from the ADAURA Phase III trial of Tagrisso (osimertinib) in the adjuvant treatment of patients …
Vivavision’s Phase IIa study of ophthalmic solution meets primary endpoints
Vivavision Biotech has reported that its Phase IIa first in human study of VVN539 Ophthalmic Solution in the US has met …
Chimeric launches Phase IB trial of glioblastoma multiforme therapy
Chimeric Therapeutics has launched a new Phase IB clinical trial of CHM 1101 (CLXT CAR T) cell therapy to treat …
Elicio reports positive interim clinical data of cancer immunotherapy study
Elicio Therapeutics has reported positive interim clinical data from its ongoing Phase I AMPLIFY-201 study evaluating its cancer immunotherapy, ELI-002, …
BioInvent receives IND approval for study of anti-TNFR2 antibody
BioInvent International has received investigational new drug (IND) approval to initiate a Phase I/IIa study of BI-1910. Compared to BioInvent’s BI-1808 …
Leading innovators with viral vectors for the pharmaceutical industry
The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, …
First patient enrolled in pulmonary hypertension reduction device study
Paris-based Gradient Denervation Technologies has performed the first procedure in its first-in-human clinical study for a pulmonary hypertension device. The …
Innovent and Merck to carry out cancer combination therapy trial
Innovent Biologics and Merck have entered a clinical trial collaboration and supply agreement for the combination therapy of IBI351 (GFH925) …
YS Biopharma receives approval for vaccine trial in Philippines
The Food and Drug Administration (FDA) of the Philippines has given approval to biopharmaceutical firm YS Biopharma to begin a …
Bluejay Therapeutics makes progress in Hepatitis B and D Trials
Bluejay Therapeutics has reported the successful completion of a Phase Ia trial and enrolment of the initial Phase Ib cohorts …